摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-异氰基苯基)-1H-吡咯 | 857283-60-4

中文名称
1-(4-异氰基苯基)-1H-吡咯
中文别名
1-(4-异氰酰基苯基)-1H-吡咯
英文名称
1-(4-Isocyanatophenyl)-1H-pyrrole
英文别名
1-(4-isocyanatophenyl)pyrrole
1-(4-异氰基苯基)-1H-吡咯化学式
CAS
857283-60-4
化学式
C11H8N2O
mdl
MFCD07772803
分子量
184.197
InChiKey
XZPOEEDBGHTYQC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    64.5-66.5

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    34.4
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2933990090

SDS

SDS:a3048540369a252af21cb73256b3bec7
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    1,2-Benzisothiazol-3-one derivatives as a novel class of small-molecule caspase-3 inhibitors
    摘要:
    A novel series of 1,2-benzisothiazol-3-one derivatives was synthesized and their biological activities were evaluated for inhibiting caspase-3 and -7 activities, in which some of them showed low nanomolar potency against caspase-3 in vitro and significant protection against apoptosis in a camptothecin-induced Jurkat T cells system. Among the tested compounds, compound 5i exhibited the most potent caspase-3 inhibitory activity (IC50 = 1.15 nM). The molecular docking predicted the interactions and binding modes of the synthesized inhibitor in the caspase-3 active site. (C) 2014 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2014.03.002
  • 作为产物:
    描述:
    4-(1-吡咯基)苯胺三光气三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 0.5h, 生成 1-(4-异氰基苯基)-1H-吡咯
    参考文献:
    名称:
    1,2-Benzisothiazol-3-one derivatives as a novel class of small-molecule caspase-3 inhibitors
    摘要:
    A novel series of 1,2-benzisothiazol-3-one derivatives was synthesized and their biological activities were evaluated for inhibiting caspase-3 and -7 activities, in which some of them showed low nanomolar potency against caspase-3 in vitro and significant protection against apoptosis in a camptothecin-induced Jurkat T cells system. Among the tested compounds, compound 5i exhibited the most potent caspase-3 inhibitory activity (IC50 = 1.15 nM). The molecular docking predicted the interactions and binding modes of the synthesized inhibitor in the caspase-3 active site. (C) 2014 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2014.03.002
点击查看最新优质反应信息

文献信息

  • INDOLINE DERIVATIVES
    申请人:Sugimoto Hachiro
    公开号:US20110294850A1
    公开(公告)日:2011-12-01
    The present invention provides a novel indoline derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or a salt thereof represented by the following formula (1) that has an excellent butyrylcholinesterase inhibitory activity. In the formula, R 1 represents an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an arylalkyl group, a heteroarylalkyl group, a cycloalkylalkyl group, a heterocycloalkylalkyl group, a dihydrofurylalkyl group, an alkenyl group, a tetrahydronaphthyl group, or an indanyl group; R 2 represents a hydrogen atom, an alkyl group, an arylalkyl group, a cycloalkylalkyl group, a heteroarylalkyl group, a heterocycloalkylalkyl group, an aryl group, or an acyl group; R 3 each independently represents a hydrogen atom, an alkyl group, or a dialkylaminocarbonyl group; R 4 each independently represents a hydrogen atom or an alkyl group; and R 5 represents a hydrogen atom or an alkyl group. Each functional group may have a substituent.
    本发明提供了一种新的吲哚啉衍生物,或者其药理学上可接受的盐,或者所述衍生物的溶剂或其盐的溶剂,其由以下式(1)所代表,具有优异的丁酰胆碱酯酶抑制活性。在该式中,R1代表烷基,环烷基,杂环烷基,芳基,杂芳基,芳基烷基,杂芳基烷基,环烷基烷基,杂环烷基烷基,二氢呋喃基烷基,烯基,四氢萘基或吲哚基;R2代表氢原子,烷基,芳基烷基,环烷基烷基,杂芳基烷基,杂环烷基烷基,芳基或酰基;R3各自独立地代表氢原子,烷基或二烷基氨基甲酰基;R4各自独立地代表氢原子或烷基;R5代表氢原子或烷基。每个功能基团可能有取代基。
  • PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT
    申请人:De Jonghe Steven Cesar Alfons
    公开号:US20090036430A1
    公开(公告)日:2009-02-05
    This invention relates to substituted pyrido(3,2-d)pyrimidine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, pro-drugs and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These derivatives are also useful in preventing or treating cardiovascular disorders, disorders of the central nervous system, TNF-α related disorders, viral diseases (including hepatitis C), erectile dysfunction and cell proliferative disorders.
    本发明涉及取代的吡啶并(3,2-d)嘧啶衍生物、它们的药学上可接受的盐、N-氧化物、溶剂化合物、前药和对映体,具有意外的理想药理特性,特别是高度活性的免疫抑制剂,因此在移植排斥和/或治疗某些炎症性疾病方面非常有用。这些衍生物还可用于预防或治疗心血管疾病、中枢神经系统疾病、TNF-α相关疾病、病毒性疾病(包括丙型肝炎)、勃起功能障碍和细胞增殖性疾病。
  • Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom
    申请人:Van Quaquebeke Eric
    公开号:US20080292585A1
    公开(公告)日:2008-11-27
    Azonafide derivatives are obtained by reacting azonafide with aldehydes, acyl halides, thioacyl halides, monoisocyanates, isothiocyanates, sulfonyl halides, monohalogenoalkanes, monohalogenoalkenes or monohalogenoalkynes, and are useful as active ingredients of pharmaceutical compositions for the prevention and treatment of cell proliferative disorders, in particular several forms of Cancer.
    Azonafide衍生物是通过将azonafide与醛类、酰卤、硫酰卤、单异氰酸酯、异硫氰酸酯、磺酰卤、单卤代烷烃、单卤代烯烃或单卤代炔烃反应得到的,并且它们可用作制药组合物的活性成分,用于预防和治疗细胞增殖性疾病,特别是几种癌症。
  • Acyclic 1,4-Diamines and Uses Thereof
    申请人:Jeong Jae U.
    公开号:US20090105259A1
    公开(公告)日:2009-04-23
    This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain acyclic diamines, which are agonists of TRPV4 channel receptors.
    本发明涉及一种新型化合物,可用于治疗与TRPV4通道受体相关的疾病。更具体地说,本发明涉及某些无环二胺,它们是TRPV4通道受体的激动剂。
  • THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES
    申请人:NV reMYND
    公开号:EP1981504B1
    公开(公告)日:2010-07-21
查看更多